Related Experiment Video

Updated: May 25, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Molecular targeting agents in the context of primary chemoradiation strategies

Simon Laban1, Chia Jung Wang, Adrian Münscher

  • 1Department of Head and Neck Surgery and Otolaryngology of the University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany. s.laban@uke.uni-hamburg.de

Head & Neck
|January 24, 2012
PubMed
Abstract

Insights

Molecular targeting agents, like epidermal growth factor receptor (EGFR) inhibitors, are increasingly used with chemoradiation for head and neck squamous cell carcinoma (HNSCC). Further trials are needed to confirm their impact on patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Radiotherapy

Background:

  • Advancements in molecular tumor biology have driven the development of molecular targeting agents.
  • These agents are integrated into chemoradiation protocols for organ preservation and improved treatment.
  • Understanding the role of molecular targeting in cancer is crucial for developing novel therapies.

Purpose of the Study:

  • To review recent clinical trials on molecular targeting agents in combination with chemoradiation for head and neck squamous cell carcinoma (HNSCC).
  • To evaluate the influence of epidermal growth factor receptor (EGFR) signaling inhibition on patient outcomes in HNSCC.
  • To discuss the current evidence for EGFR targeting agents in primary chemoradiation.

Main Methods:

  • Systematic literature review of clinical trials.
  • Analysis of data from recent studies combining chemoradiation with EGFR targeting agents.
  • Focus on head and neck squamous cell carcinoma (HNSCC) treatment.

Main Results:

  • Inhibition of epidermal growth factor receptor (EGFR) signaling is a key strategy in HNSCC management.
  • While EGFR targeting agents are common, their precise impact on patient outcomes requires further clarification.
  • Current data from clinical trials show promising, yet not fully elucidated, results for combined therapies.

Conclusions:

  • Promising results from recent trials warrant confirmation in larger patient cohorts.
  • Cost-effectiveness analyses are necessary to determine the value of these targeted therapies.
  • Further Phase III studies are essential to validate findings from Phase II trials before widespread adoption.

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids05:39

Live Imaging to Quantify Cellular Radiosensitivity in Patient-Derived Tumor Organoids

Published on: April 5, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...